Accolades ADial PharmaceuticalsTM LLC and Tau Therapeutics LLC were named finalists for the Virginia Biotechnology Association’s 2011 Virginia Bioscience Company of the Year Award in May. The award recognizes the firm with strong overall perfor...
Twelve biotechnology firms with roots at the University of Virginia were awarded grants totaling more than $2.7 million under a new federal program. Established as part of the Affordable Care Act, enacted this spring, the Qualified Therapeutic Disco...
University of Virginia spin-out PluroGen Therapeutics Inc. commemorated the start of the company's new relationship with the U.S. Department of Defense at a reception held Nov. 5 on U.Va. Grounds. PluroGen recently entered into an agreement worth up ...
It’s frightening to think that only 15 years ago burn victims faced often insurmountable risks of infection, even in quality treatment facilities. And patients suffering from chronic wounds, such as diabeticulcers, pressure ulcers and venous leg ulce...
Burn victims suffer a unique agony. The pain of their injury is compounded by the rigorous cleansing required to ward off infection, a common and often fatal complication. The work of George T. Rodeheaver, a professor in the U.Va. Department of Plast...
A University of Virginia professor is being honored as the inventor of the year for a gel that treats burns and chronic wounds. The University of Virginia Patent Foundation named George T. Rodeheaver, a 36-year veteran in the U.Va. Department of Plas...
The University of Virginia Patent Foundation has licensed innovative U.Va. silver nanoparticle technology to U.Va. start-up PluroGen Therapeutics Inc. for use as an enhanced anti-microbial agent to fight infection and promote wound-healing. Silver ha...